![]() |
市場調查報告書
商品編碼
1754079
2025-2033年口腔潰瘍治療市場(按劑型、藥物類別、適應症和地區)報告Mouth Ulcer Treatment Market Report by Formulation, Drug Class, Indication, and Region 2025-2033 |
2024年,全球口腔潰瘍治療市場規模達19.7億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到25.5億美元,2025-2033年期間的複合年成長率(CAGR)為2.74%。該市場正在經歷顯著成長,主要原因是口腔健康問題發病率的上升、人們對治療方案的認知度不斷提高以及對非處方藥需求的不斷成長。藥物配方的進步、醫療保健服務的普及以及消費者對速效止痛口腔潰瘍治療產品的偏好,也對市場成長做出了積極貢獻。
配方創新
為了滿足消費者對快速緩解和治癒口腔潰瘍的需求,各公司正在開發速效口腔潰瘍治療方法。這些創新產品包括外用凝膠、漱口水和藥用貼劑,旨在減輕疼痛並在數小時內加速康復。先進的配方著重透過速效吸收或緩釋發揮標靶作用,從而提供持久的療效。這一趨勢源自於消費者對便利性的期望,即產品能夠快速緩解症狀,同時易於塗抹。這些快速解決方案在繁忙的生活方式中也頗具吸引力,因為人們非常重視無需處方即可快速治療。此外,根據2024年發表在《歐洲藥劑學和生物藥劑學雜誌》上的一篇文章,創新型丁香酚和硼砂基口腔崩解膜(ODF)的開發已成為治療口腔疾病(包括口腔潰瘍)傳統方法的首選替代方案,其療效更為有效。 ODF 是一種超薄、郵票大小、便於攜帶、患者友好且親水的薄膜,可在舌頭或口腔區域數秒內溶解崩解,無需用水或吞嚥。這種給藥方式在兒童、老年人以及患有吞嚥困難的特殊患者族群中尤其常見。
電子商務通路的成長
隨著越來越多的消費者為了方便起見而轉向線上購物,口腔潰瘍治療產品的電商通路成長正在加速。線上平台提供更廣泛的產品選擇,包括各種天然藥物、非處方藥和專科治療藥物,這些藥物可能在當地藥局買不到。消費者可以輕鬆比較價格、閱讀評論並快速收到產品,通常還可以享受折扣或訂閱服務。此外,電子藥局和數位健康平台的興起也提高了這些治療藥物的可用性和可近性,從而促進了市場的線上銷售。例如,根據 IMARC 的數據,全球電子藥局市場規模在 2023 年達到 942 億美元。展望未來, IMARC Group預計到 2032 年該市場將達到 3,141 億美元,在 2024-2032 年期間的複合年成長率 (CAGR) 為 14.32%。此外,亞馬遜藥局於 2024 年 6 月宣布,計劃將其訂閱服務擴展到醫療保險計劃的參保者。此次擴展將惠及超過 5,000 萬名醫療保險受益人,他們將可以使用亞馬遜藥房的處方訂閱服務 RxPass
轉向天然和草本產品
由於擔心合成藥物的潛在副作用,消費者擴大轉向使用天然和草本產品來治療口腔潰瘍。蘆薈、洋甘菊和甘草等成分因其舒緩和治癒功效而備受青睞。這種轉變源於人們對健康的廣泛關注,因為人們更傾向於有機和無化學成分的解決方案,以符合注重健康的生活方式。對此類療法日益成長的需求促使企業開發更多迎合此趨勢的植物性產品,使天然替代品在市場上廣泛普及。根據口腔潰瘍治療市場概況,消費者對天然和草本療法日益成長的偏好預計將推動市場顯著成長,更多公司將投資植物性配方,以滿足對有機、無化學成分解決方案日益成長的需求。例如,2023年11月,邁阿密大學牙科學院的學生宣布開發了從果皮中提取的生態酶,用於治療口腔潰瘍。團隊將各種水果和植物的果皮加工成生態酶,旨在加速口腔潰瘍的癒合。實驗室對大鼠的研究顯示出良好的效果,生態酵素貼片可以減少口腔潰瘍傷口中的發炎細胞。雖然該研究尚處於早期階段,且僅在動物身上進行過測試,但仍需進一步進行全面的研究,以確保其對人類使用的安全性和有效性。
凝膠佔據大部分市場佔有率
根據口腔潰瘍治療市場報告,凝膠因其快速起效和精準緩解的特徵佔據市場主導地位。凝膠使用方便,能夠在潰瘍表面形成保護膜,從而有效緩解疼痛並加速癒合。凝膠通常含有抗菌劑、止痛藥和消炎藥等活性成分,一次使用即可提供全面的治療。凝膠能夠停留在潰瘍部位,相較於漱口水或含片等其他劑型,其緩解效果更持久。這種便利性和有效性使其廣受消費者青睞。
皮質類固醇佔產業最大佔有率
皮質類固醇因其強大的抗發炎和免疫抑制特性,在口腔潰瘍治療領域佔最大佔有率。這些藥物能有效減輕口腔潰瘍引起的腫脹、疼痛和刺激,促進更快癒合。皮質類固醇通常用於治療嚴重或復發性潰瘍,例如口瘡性口炎,而非處方藥的效果可能較差。皮質類固醇能夠標靶作用於潛在炎症,使其成為醫護人員的首選。此外,凝膠和軟膏等外用皮質類固醇製劑的進步,透過局部緩解症狀並最大程度地減少全身性副作用,提高了患者的依從性。這些因素正在為口腔潰瘍治療市場創造積極的前景,並推動對皮質類固醇類產品的需求,因為它們在治療嚴重潰瘍方面療效顯著。
口瘡性口炎代表了領先的市場
口瘡性口炎,俗稱口腔潰瘍,因其在世界各地廣泛流行,佔據口腔潰瘍治療市場的主導地位。此病的特徵是口腔內反覆出現疼痛性潰瘍,通常由壓力、損傷或營養不良引發。由於患者尋求快速緩解不適並加速癒合,對皮質類固醇、凝膠和抗菌漱口水等有效治療方法的需求很高。口瘡性口炎的慢性和復發性特性推動了對非處方藥和處方藥的持續需求。口腔潰瘍治療市場的動態進一步受到對創新且易於獲取的解決方案的需求的影響,這些解決方案用於管理口瘡性口炎的慢性和復發性,從而導致治療方案的不斷改進和製藥公司之間競爭的加劇。根據美國國家醫學圖書館2023年5月發表的一篇文章,全球約25%的人口患有復發性口瘡性口炎(RAS),這是一種常見的口腔黏膜疾病。遺傳、營養不良、壓力和免疫功能障礙等因素都可能導致此病。如此高的盛行率凸顯了市場對有效治療和預防解決方案的巨大需求。因此,製藥公司正致力於開發標靶療法,以解決RAS的根本病因,同時最大限度地降低復發率並改善患者預後。
北美引領市場,佔據口腔潰瘍治療市場最大佔有率
該報告還對所有主要區域市場進行了全面分析,包括北美、歐洲、亞太地區、中東和非洲、拉丁美洲。報告指出,北美是口腔潰瘍治療最大的區域市場。
北美引領全球口腔潰瘍治療市場,佔最大佔有率,這得益於該地區較高的口腔健康意識和先進的醫療服務。口瘡性口炎和其他口腔潰瘍等疾病的盛行率很高,推動了對非處方藥和處方藥的需求。該地區成熟的製藥業支持有效治療方法的開發和普及,例如皮質類固醇、凝膠和漱口水。此外,對研發和創新的重視以及優惠的醫保報銷政策也促進了市場成長。人們對速效止痛產品的日益青睞進一步鞏固了北美在該市場的領導地位。根據口腔潰瘍治療市場預測,北美預計將繼續保持領先地位,並在治療方案的不斷進步、對創新療法的需求不斷成長以及口腔健康管理意識不斷提高的推動下實現穩步成長。例如,2023年11月,MidAmerica Pharmaceuticals推出了Kourzeq™,這是一款經FDA批准的用於治療口腔潰瘍的新型牙膏。該牙膏含有曲安奈德,旨在暫時緩解口腔發炎和潰瘍性病變並進行輔助治療。 Kourzeq僅透過BeyondMD的遠距醫療平台提供,旨在為口腔潰瘍患者帶來正面的影響。
The global mouth ulcer treatment market size reached USD 1.97 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.55 Billion by 2033, exhibiting a growth rate (CAGR) of 2.74% during 2025-2033. The market is experiencing significant growth mainly driven by rising incidences of oral health issues, an increased awareness of treatment options and the growing demand for over-the-counter remedies. Advancements in pharmaceutical formulations, expanding healthcare access and consumer preference for fast-acting, pain-relief products to treat mouth ulcers are also contributing positively to the market growth.
Innovation in Formulations
Companies are developing fast-acting mouth ulcer treatments to address the consumer demand for quicker relief and healing. These innovations include topical gels, oral rinses, and medicated patches designed to minimize pain and accelerate recovery within hours. Advanced formulations focus on delivering targeted action through immediate absorption or sustained release, providing long-lasting effects. This trend is driven by consumer expectations for convenience, with products that offer swift relief while being easy to apply. These rapid solutions are also appealing in busy lifestyles where quick treatment without the need for prescriptions is highly valued. Furthermore, according to an article published in the European Journal of Pharmaceutics and Biopharmaceutics in 2024, the development of innovative eugenol and borax-based orodispersible films (ODFs) have emerged as the preferred alternative to traditional methods of treating oral diseases, including mouth ulcers, with a much more efficient results. ODFs are ultra-thin, stamp-sized, portably-used, patient-friendly, and hydrophilic films that dissolve and disintegrate within seconds on the tongue or buccal area without the need of water or swallowing. This administration is particularly prevalent among pediatric, geriatric, and special patient populations who have dysphagia.
Growth in E-Commerce Channels
Growth in e-commerce channels for mouth ulcer treatments is accelerating as more consumers shift toward online shopping for convenience. Online platforms offer a wider selection of products, including various natural, OTC, and specialized treatments, which may not be available in local pharmacies. Consumers benefit from the ease of comparing prices, reading reviews, and receiving products quickly, often with discounts or subscription services. Additionally, the rise of e-pharmacies and digital health platforms has contributed to the increased availability and accessibility of these treatments, boosting online sales in the market. For instance, according to IMARC, the global e-pharmacy market size reached US$ 94.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 314.1 Billion by 2032, exhibiting a growth rate (CAGR) of 14.32% during 2024-2032. Furthermore, Amazon Pharmacy announced in June 2024 that it intends to expand its subscription service to enrollees of Medicare insurance plans. The expansion will be available to more than 50 million Medicare beneficiaries, who will have access to RxPass, Amazon Pharmacy's subscription prescription service
Shift Towards Natural and Herbal Products
Consumers are increasingly turning to natural and herbal products for mouth ulcer treatment due to concerns about the potential side effects of synthetic medications. Ingredients like aloe vera, chamomile, and licorice are favored for their soothing and healing properties. This shift is driven by a broader focus on wellness, as people prefer organic and chemical-free solutions that align with health-conscious lifestyles. The growing demand for such treatments is encouraging companies to develop more plant-based products that cater to this trend, making natural alternatives widely available across the market. According to the mouth ulcer treatment market overview, this rising consumer preference for natural and herbal remedies is expected to drive significant growth, with more companies investing in plant-based formulations to meet the increasing demand for organic, chemical-free solutions. For instance, in November 2023, UGM Dentistry students announced the development of eco-enzymes from fruit peels for mouth ulcer treatment. The team processed peels from various fruits and plants into eco-enzymes, aiming to accelerate mouth ulcer healing. Laboratory research on rats showed promising results, with the eco-enzyme patch reducing inflammatory cells in mouth ulcer wounds. While the research is in early stages and tested only on animals, further comprehensive studies are required to ensure its safety and efficacy for human use.
Gel accounts for the majority of the market share
According to mouth ulcer treatment market report, gel dominate the market due to their fast-acting and targeted relief. Their easy application and ability to form a protective barrier over the ulcer make them highly effective in soothing pain and accelerating healing. Gels often contain active ingredients like antiseptics, pain relievers, and anti-inflammatory agents, providing comprehensive treatment in a single application. Their ability to stay localized at the site of the ulcer allows for longer-lasting relief compared to other forms, such as mouthwashes or lozenges. This convenience and effectiveness have led to their widespread preference among consumers.
Corticosteroids holds the largest share of the industry
Corticosteroids hold the largest share of the mouth ulcer treatment industry due to their powerful anti-inflammatory and immunosuppressive properties. These medications effectively reduce swelling, pain, and irritation associated with mouth ulcers, promoting faster healing. Corticosteroids are often prescribed for severe or recurrent cases of ulcers, such as aphthous stomatitis, where over-the-counter treatments may be less effective. Their ability to target the underlying inflammation makes them a preferred choice among healthcare professionals. Additionally, advancements in topical corticosteroid formulations, like gels and ointments, have improved patient compliance by offering localized relief with minimal systemic side effects. These factors are creating a positive mouth ulcer treatment market outlook, driving the demand for corticosteroid-based products due to their efficacy in managing severe ulcer cases.
Aphthous Stomatitis represents the leading market segment
Aphthous stomatitis, commonly known as canker sores, represents the leading segment in the mouth ulcer treatment market due to its high prevalence among individuals worldwide. This condition is characterized by recurrent, painful ulcers in the mouth, often triggered by stress, injury, or nutritional deficiencies. The demand for effective treatments, such as corticosteroids, gels, and antiseptic mouthwashes, is high as patients seek fast relief from discomfort and accelerated healing. The chronic and recurrent nature of aphthous stomatitis drives the consistent demand for both over-the-counter and prescription treatments. The mouth ulcer treatment market dynamics are further influenced by the need for innovative and accessible solutions to manage the chronic and recurrent nature of aphthous stomatitis, leading to continuous advancements in treatment options and increased competition among pharmaceutical companies. According to an article published in May 2023 by National Library of Medicine, approximately 25% of the global population is affected by recurrent aphthous stomatitis (RAS), a common oral mucosal disease. Factors such as genetics, nutritional deficiencies, stress, and immune dysfunction contribute to the condition. This high prevalence underscores the significant demand for effective treatments and preventive solutions in the market. As a result, pharmaceutical companies are focusing on developing targeted therapies that address the underlying causes of RAS while minimizing recurrence and improving patient outcomes.
North America leads the market, accounting for the largest mouth ulcer treatment market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Middle East and Africa, Latin America. According to the report, North America represents the largest regional market for mouth ulcer treatment.
North America leads the global mouth ulcer treatment market, accounting for the largest share due to the region's high awareness of oral health and access to advanced healthcare services. The prevalence of conditions like aphthous stomatitis and other oral ulcers is significant, driving the demand for both over-the-counter and prescription treatments. The region's well-established pharmaceutical industry supports the development and availability of effective treatments, such as corticosteroids, gels, and mouthwashes. Additionally, the focus on research and innovation, along with favorable healthcare reimbursement policies, boosts market growth. The increasing preference for fast-acting, pain-relief products further strengthens North America's leadership in this market. According to mouth ulcer treatment market forecast, North America is expected to continue to lead, with steady growth driven by ongoing advancements in treatment options, rising demand for innovative therapies, and increasing awareness of oral health management. For instance, in November 2023, MidAmerica Pharmaceuticals introduced Kourzeq(TM), a new FDA-approved dental paste for treating canker sores. The paste, containing triamcinolone acetonide, is designed to provide temporary relief and adjunctive treatment for oral inflammatory and ulcerative lesions. Available exclusively through telehealth via BeyondMD, Kourzeq aims to make a positive impact on those suffering from canker sores.